One-Day TMS for Depression (Free 15-Min Consultation)

Traditional TMS requires daily visits over many weeks - a significant barrier for people with work, family, or travel constraints. ONE-D addresses that barrier by delivering an intensive therapeutic treatment course in a single, tightly supervised day, while keeping the same safety and personalization steps used in standard and other accelerated TMS protocols. Early clinical reports and pilot data show encouraging response and remission rates (>70% response and near 50% remission) when conducted under careful clinical conditions.

iTBS format: ONE-D uses repeated blocks of intermittent Theta Burst Stimulation (iTBS). Each iTBS block is brief (as little as 3 minutes), but the full 20-session schedule builds a cumulative neuroplastic effect.

High density, short intervals: Repeats many short sessions with short rest periods; the accumulated stimulation aims to produce a stronger, faster biological shift. 600 pulses of iTBS are delivered every 30 minutes in just one day.

Medication augmentation: Neuroplastogens (D-cycloserine and Vyvanse) are added the morning of treatments to enhance neuroplasticity — always under careful psychiatric supervision and informed consent.

Individualized mapping & monitoring: Motor-threshold mapping and personalized targeting based on updated scalp heuristics are used before the session so stimulation is safe and tailored to you.

Option	Sessions	Typical timing	Insurance
Standard TMS	36+	8 weeks	Often covered
5-day Accelerated TMS	50	5 days (10/day)	Self-pay ($7000)
ONE-D	20	1 Day	Self-pay ($3,000)

Several pilot and case-series on highly accelerated, neuroplastogen-enhanced protocols report high early response/remission rates (for example, single-day/accelerated protocols with up to ~90% response and ~74% remission rates at 6–12 weeks). These are promising early results; large randomized trials and longer-term follow-up remain an area of active study.

Accelerated protocols such as 50 sessions in 5 days (SAINT-style) have likewise demonstrated strong outcomes in trials and real-world clinic experience; ONE-D builds on that paradigm by intensifying delivery.